Sarepta Therapeutics Inc (SRPT)

Currency in USD
17.18
+0.40(+2.38%)
Closed·
17.180.00(0.00%)
·

SRPT Comments

This will tank tomorrow
Updated label huge positive. FDA will definitely not pull elevidys. Very Undervalued on ambulatory population alone
-37% wich is usual on earnings day.
Roche just stated that Sarepta's drug had 89% growth increase in the quarter. if the US sales are close.enough you get a bullish quarter
Advertisement
STRONG BUY
STRONG BUY LONG SAREPTA
pro badge
SRPT is been under valued for sometime, what is ii missing?
STRONG BUY LONG
Advertisement
pro badge
Lets roll
STRONG
BUY
wallstreetbets ⚠️⚠️⚠️
Advertisement
BUY back $500 000 000 STRONG
STRONG BUY LONG $50
pro badge
what basis ? even after FDA clearance it's been stalled
pro badge
everything about competition with Pfizer.
pro badge
Stock on sale !!
STRONG BUY
Advertisement
Insiders dumping the atick just before coosing three days in a row. That tells you something.
Rebound to ~60
can tske months, lot of sellers at 22, better join them
pro badge
Fly baby fly !!!
pro badge
Fly baby fly !!!
Advertisement
pro badge
Amazing how it one year stock can fall from 150 bucks a share to this unbelievable
Buy back in when it hits $10.00
From 10.42 to 19, good call
pro badge
Still no response from FDA ?
Patients death during trial
No patients will remain alive until the end of the tests.
Buying as much as I can. Go Sarepta go
Advertisement
Just panic sell, this is gonna 3x from now till end of the year!
I need 130% to breakeven
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.